Two Ludwig researchers elected to National Academy of Medicine

Ludwig Stanford’s Maximilian Diehn and Michelle Monje were elected to the National Academy of Medicine in October. Max was recognized for “developing and clinically translating novel diagnostic technologies for facilitating precision medicine techniques, and for integrating advanced precision medicine into the area of liquid biopsies.” He has made major contributions to the development of several sophisticated technologies for tissue analysis, the early detection of malignancies and the prediction of patient prognoses and treatment outcomes. Several of his lab’s discoveries and technologies are currently being evaluated in clinical trials. Michelle was recognized for “making groundbreaking discoveries at the intersection of neurodevelopment, neuroplasticity and brain tumor biology.” An authority on diffuse intrinsic pontine glioma, Michelle has pioneered the development of new therapies now in clinical trials for the devastating pediatric brain tumor. She has, in addition, made groundbreaking discoveries on the neuroscience of pediatric and adult brain tumors and the cognitive effects of chemotherapy that hold great promise for translational development. Earlier last year, Michelle also received the MacArthur Award, given “to talented individuals in a variety of fields who have shown exceptional originality in and dedication to their creative pursuits.” Click here for a short video of Michelle describing her work and here and here for our profiles of Michelle and Max.

This article appeared in the February 2022 issue of Ludwig Link. Click here to download a PDF (1 MB).


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?